Thrombotic and hemorrhagic events in 2016 World Health Organization-defined Philadelphianegative myeloproliferative neoplasm
2
조회
0
다운로드
5
인용
0
참고문헌
키워드
초록
Background/Aims: Recent changes in the diagnostic criteria for myeloproliferative neoplasms (MPNs) and increasing patient numbers necessitate updating of the data on vascular events in patients with such disorders. Methods: In this single-center study, thrombotic and hemorrhagic events were retrospectively analyzed in patients diagnosed with essential thrombocythemia (ET), polycythemia vera (PV) prefibrotic/early primary myelofibrosis (pre-PMF), or PMF, based on the 2016 World Health Organization diagnostic criteria. Results: Of a total of 335 consecutive patients (139 ET, 42 pre-PMF, 124 PV, and 30 PMF patients; 192 males and 143 females) of median age 64 years (range, 15 to 91), 112 (33.4%) experienced a total of 126 thrombotic events before diagnosis, at the time of diagnosis, or during follow-up over a median of 4.6 years (range, 0.1 to 26.5). Cerebrovascular thrombosis (18.8%) was the most common initial event, followed by coronary heart disease (10.1%) and splanchnic (1.5%) and peripheral thrombosis (1.5%). Arterial thrombosis was more common than venous thrombosis (31.3% vs. 2.1%, respectively; p = 0.001). Thrombosis was most frequent in PV patients (39.5%), followed by patients with pre-PMF (38.1%), ET (30.9%), and PMF (13.3%). Of the 112 patients who experienced thromboses, 53 (47%) and 39 (33.9%) had thrombotic events before and at the time of MPN diagnosis, respectively. Twenty-seven patients (8.1%) experienced 29 hemorrhagic events, of which gastrointestinal bleeding (n = 20) was the most common. Conclusions: Most thrombotic events occurred before or at the time of diagnosis, and the prevalence of arterial thrombosis was markedly higher than that of venous thrombosis in patients with MPN.
Abstract
Background/Aims: Recent changes in the diagnostic criteria for myeloproliferative neoplasms (MPNs) and increasing patient numbers necessitate updating of the data on vascular events in patients with such disorders. Methods: In this single-center study, thrombotic and hemorrhagic events were retrospectively analyzed in patients diagnosed with essential thrombocythemia (ET), polycythemia vera (PV) prefibrotic/early primary myelofibrosis (pre-PMF), or PMF, based on the 2016 World Health Organization diagnostic criteria. Results: Of a total of 335 consecutive patients (139 ET, 42 pre-PMF, 124 PV, and 30 PMF patients; 192 males and 143 females) of median age 64 years (range, 15 to 91), 112 (33.4%) experienced a total of 126 thrombotic events before diagnosis, at the time of diagnosis, or during follow-up over a median of 4.6 years (range, 0.1 to 26.5). Cerebrovascular thrombosis (18.8%) was the most common initial event, followed by coronary heart disease (10.1%) and splanchnic (1.5%) and peripheral thrombosis (1.5%). Arterial thrombosis was more common than venous thrombosis (31.3% vs. 2.1%, respectively; p = 0.001). Thrombosis was most frequent in PV patients (39.5%), followed by patients with pre-PMF (38.1%), ET (30.9%), and PMF (13.3%). Of the 112 patients who experienced thromboses, 53 (47%) and 39 (33.9%) had thrombotic events before and at the time of MPN diagnosis, respectively. Twenty-seven patients (8.1%) experienced 29 hemorrhagic events, of which gastrointestinal bleeding (n = 20) was the most common. Conclusions: Most thrombotic events occurred before or at the time of diagnosis, and the prevalence of arterial thrombosis was markedly higher than that of venous thrombosis in patients with MPN.
참고문헌 (29)
- Stein BL, "From Budd-Chiari syndrome to acquired von Willebrand syndrome : thrombosis and bleeding complications in the myeloproliferative neoplasms", Hematology Am Soc Hematol Educ Program, 2019, pp.397~406 (2019)
- Rungjirajittranon T, "A systematic review and meta-analysis of the prevalence of thrombosis and bleeding at diagnosis of Philadelphia-negative myeloproliferative neoplasms", BMC Cancer, 19, pp.184~ (2019)
- GBD 2016 Lifetime Risk of Stroke Collaborators, "Global, regional, and country-specific lifetime risks of stroke, 1990 and 2016", N Engl J Med, 379, pp.2429~2437 (2018)
- Andre R, "International differences in acute coronary syndrome patients’ baseline characteristics, clinical management and outcomes in Western Europe : the EURHOBOP study", Heart, 100, pp.1201~1207 (2014)
- Bang SM, "Vascular events in Korean patients with myeloproliferative neoplasms and their relationship to JAK2 mutation", Thromb Haemost, 101, pp.547~551 (2009)
- Lee HS, "Incidence rates and risk factors for vascular events in patients with essential thrombocythemia : a multicenter study from Korea", Clin Lymphoma Myeloma Leuk, 12, pp.70~75 (2012)
- Lim Y, "Prediction of thrombotic and hemorrhagic events during polycythemia vera or essential thrombocythemia based on leukocyte burden", Thromb Res, 135, pp.846~851 (2015)
- Wasserman LR, "Polycythemia vera study group : a historical perspective", Semin Hematol, 23, pp.183~187 (1986)
- Michiels JJ, "Proposal for revised diagnostic criteria of essential thrombocythemia and polycythemia vera by the Thrombocythemia Vera Study Group", Semin Thromb Hemost, 23, pp.339~347 (1997)
- Vardiman JW, "The 2008 revision of the World Health Organization(WHO)classification of myeloid neoplasms and acute leukemia : rationale and important changes", Blood, 114, pp.937~951 (2009)
- Arber DA, "The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia", Blood, 127, pp.2391~2405 (2016)
- Jeryczynski G, "Pre-fibrotic", early primary myelofibrosis vs. WHO-defined essential thrombocythemia: the impact of minor clinical diagnostic criteria on the outcome of the disease, 2017, pp.92, 885~891
- Gisslinger H, "Clinical impact of bone marrow morphology for the diagnosis of essential thrombocythemia : comparison between the BCSH and the WHO criteria", Leukemia, 30, pp.1126~1132 (2016)
- Kamiunten A, "Early", prefibrotic primary myelofibrosis in patients who were initially diagnosed with essential thrombocythemia, 2018, pp.108, 411~415
- Barbui T, "Diagnostic impact of the 2016 revised who criteria for polycythemia vera", Am J Hematol, 92, pp.417~419 (2017)
- Edahiro Y, "Clinical and molecular features of patients with prefibrotic primary myelofibrosis previously diagnosed as having essential thrombocythemia in Japan", Eur J Haematol, 102, pp.516~520 (2019)
- 최철원, "Guidelines for the management of myeloproliferative neoplasms", The Korean Journal of Internal Medicine, 30(6), pp.771~788 (2015), 대한내과학회[DOI]
- 임유주, "Incidence, Survival and Prevalence Statistics of Classical Myeloproliferative Neoplasm in Korea", Journal of Korean Medical Science, 31(10), pp.1579~1585 (2016), 대한의학회
- Byun JM, "Real world epidemiology of myeloproliferative neoplasms : a population based study in Korea 2004-2013", Ann Hematol, 96, pp.373~381 (2017)
- Kaifie A, "Bleeding, thrombosis, and anticoagulation in myeloproliferative neoplasms(MPN) : analysis from the German SAL-MPN-registry", J Hematol Oncol, 9, pp.18~ (2016)
- Vianello F, "Coronary microvascular dysfunction due to essential thrombocythemia and policythemia vera: the missing piece in the puzzle of their increased cardiovascular risk?", Am J Hematol, 90, pp.109~113 (2015)
- Guadall A, "Endothelial cells harbouring the JAK2V617F mutation display pro-adherent and pro-thrombotic features", Thromb Haemost, 118, pp.1586~1599 (2018)
- Guy A, "Vascular endothelial cell expression of JAK2V617F is sufficient to promote a pro-thrombotic state due to increased P-selectin expression", Haematologica, 104, pp.70~81 (2019)
- Castiglione M, "Endothelial JAK2V617F mutation leads to thrombosis, vasculopathy, and cardiomyopathy in a murine model of myeloproliferative neoplasm", J Thromb Haemost, 18, pp.3359~3370 (2020)
- Passamonti F, "A prognostic model to predict survival in 867 World Health Organization-defined essential thrombocythemia at diagnosis : a study by the International Working Group on Myelofibrosis Research and Treatment", Blood, 120, pp.1197~1201 (2012)
- Barbui T, "Development and validation of an International Prognostic Score of thrombosis in World Health Organization-essential thrombocythemia(IPSET-thrombosis)", Blood, 120, pp.5128~5133 (2012)
- Haider M, "Validation of the revised international prognostic score of thrombosis for essential thrombocythemia(IPSET-thrombosis)in 585mayo clinic patients", Am J Hematol, 91, pp.390~394 (2016)
- Barbui T, "The new WHO classification for essential thrombocythemia calls for revision of available evidences", Blood Cancer J, 10, pp.22~ (2020)
- Finazzi G, "Incidence and risk factors for bleeding in 1104 patients with essential thrombocythemia or prefibrotic myelofibrosis diagnosed according to the 2008 WHO criteria", Leukemia, 26, pp.716~719 (2012)